NCT05546398

Brief Summary

In this study, a survey of office-based cardiologists and lipid management specialists will be conducted on treatment decisions for NUSTENDI® (bempedoic acid 180 mg fixed dose combination \[FDC\] with ezetimibe 10 mg) followed by a retrospective chart review of patients at high and very-high cardiovascular risk with hypercholesterolemia or mixed dyslipidemia who were treated with FDC as add-on to treatment with maximally tolerated statin therapy in routine clinical practice.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2022

Shorter than P25 for all trials

Geographic Reach
1 country

63 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 22, 2022

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

September 14, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 19, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 17, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 17, 2022

Completed
Last Updated

December 1, 2022

Status Verified

November 1, 2022

Enrollment Period

7 months

First QC Date

September 14, 2022

Last Update Submit

November 30, 2022

Conditions

Keywords

HypercholesterolemiaMixed dyslipidemiaNUSTENDI®Statin therapy

Outcome Measures

Primary Outcomes (7)

  • Low density Lipoprotein-Cholesterol (LDL-C) Levels at Therapy Decision Based on Physician Survey

    Physicians will be surveyed to assess the LDL-C levels at the time of a therapy decision.

    Up to 6 months

  • Reductions in Low density Lipoprotein-Cholesterol (LDL-C) Levels Based on Physician Survey

    Physicians will be surveyed to determine their anticipated reductions in LDL-C levels as a result of therapy.

    Up to 6 months

  • Visual Analogue Scale (VAS) Score Evaluating Relevance of Decision Factors and Considerations Relevant to Therapy Decision Based on Physician Survey

    Physicians will be surveyed to determine the relevance of decision factors and considerations (including guidelines) that were relevant to their therapy decision based on a VAS ranging from 0 to 10.

    Up to 6 months

  • Low density Lipoprotein-Cholesterol (LDL-C) Levels at Therapy Decision Based on a Retrospective Patient Chart Review

    A retrospective patient chart review will assess the LDL-C levels at the time of a therapy decision.

    Up to 6 months

  • Number of Participants With Pre-specified Events in Their Medical History Based on a Retrospective Patient Chart Review

    A retrospective patient chart review will assess the number of participants with pre-specified events in their medical history.

    Up to 6 months

  • Number of Participants With Specific Concomitant Diseases Based on a Retrospective Chart Review

    A retrospective patient chart review will assess the number of participants with specific concomitant diseases.

    Up to 6 months

  • Number of Participants Implementing Specific Lifestyle Modifications Based on a Retrospective Patient Chart Review

    A retrospective patient chart review will assess the number of participants with specific lifestyle modifications.

    Up to 6 months

Study Arms (2)

Physicians

Office-based cardiologists (OBCs) and lipid management specialists (LMSs) who are qualified for study participation regarding experience in lipid management therapy and treating a sufficient number of patients.

Other: No study drug

High and Very High Cardiovascular Patients

Patients at high and very high cardiovascular risk as assessed by the office-based cardiologists and lipid management specialists with hypercholesterolemia or mixed dyslipidemia who received a prescription of bempedoic acid 180 mg fixed dose combination with ezetimibe 10 mg (FDC).

Drug: Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab

Interventions

No study drug was administered during this study.

Also known as: NUSTENDI®
High and Very High Cardiovascular Patients

No study drug was administered during this study.

Physicians

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

For the physician survey, office-based cardiologists and lipid management specialists must be qualified for study participation regarding experience in lipid management therapy and treating a sufficient number of patients. The office-based cardiologists and lipid management specialists will be preselected by the Medical Science Liaison Managers of DSDE. The retrospective patient chart review will include patients at high and very high cardiovascular risk as assessed by the office-based cardiologists and lipid management specialists with hypercholesterolemia or mixed dyslipidemia who received a prescription of FDC for at least 4 weeks.

You may qualify if:

  • Eligibility criteria for the office-based cardiologists and lipid management specialists are as follows:
  • More than 10 years of experience in medical practice
  • For office-based cardiologists: Supervision of at least 200 patients at high and very high cardiovascular risk as assessed by the office-based cardiologists with hypercholesterolemia or mixed dyslipidemia. For lipid management specialists: Supervision of at least 500 patients at high and very high cardiovascular risk as assessed by the lipid management specialists with hypercholesterolemia or mixed dyslipidemia
  • Working in practices to whom patients were either referred or had direct access to.
  • Availability to share medical files of consenting patients with study personnel (e.g. Clinical Research Associates) by remote quality review
  • At least 5 patients for the retrospective chart review
  • Written informed consent to participate
  • Patients at high and very high cardiovascular risk diagnosed with hypercholesterolemia or mixed dyslipidemia and treated with bempedoic acid 180 mg fixed dose combination with ezetimibe 10 mg (FDC) for at least 4 weeks at the discretion of the physician according to the German label

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (63)

Kardiologische Gemeinschaftspraxis (Bulut)

Arnsberg, Germany

Location

Dr. Georg Strack

Bad König, Germany

Location

Dr. J. Nothroff

Berlin, Germany

Location

Kardiologie am Spreebogen (Krackhardt)

Berlin, Germany

Location

Kardiologie Spreebogen Berlin (Haverkamp)

Berlin, Germany

Location

Kardiologische Facharztpraxis Winkelmann

Berlin, Germany

Location

SPK-Studienzentrum Rankestraße GmbH

Berlin, Germany

Location

Kardio Bonn

Bonn, Germany

Location

Dr. Jaroslaw Sek

Chemnitz, Germany

Location

Praxis Dipl.-med. Schermaul

Chemnitz, Germany

Location

Praxis für Kardiologie und Schlafmedizin (Lichtenberg)

Cologne, Germany

Location

BAG Helmecke

Crivitz, Germany

Location

Kardiologie Darmstadt

Darmstadt, Germany

Location

MVZ Rhein-Main GmbH (Binder)

Dreieich, Germany

Location

Cardiologicum Dresden / Pirna (Hildebrandt)

Dresden, Germany

Location

Facharztzentrum Dresden-Neustadt GbR (Simonis)

Dresden, Germany

Location

PD Dr. Stephan Wiedemann

Dresden, Germany

Location

Praxis Dr. Methfessel

Dresden, Germany

Location

KardioPraxis Rote Straße (Stieber)

Duisburg, Germany

Location

Kardiologische Praxis (Warzok)

Gotha, Germany

Location

Kardiopraxis Greiz (Walter)

Greiz, Germany

Location

MVZ des Krankenhaus Greiz

Greiz, Germany

Location

Kardiologie am Tibarg (Twisselmann)

Hamburg, Germany

Location

Diabetiker Zentrum Hannover (Fendler)

Hanover, Germany

Location

Kardiologie Haßloch (Gerhards)

Haßloch, Germany

Location

Kardiologie Alsterquelle

Henstedt-Ulzburg, Germany

Location

Praxis Dr. Lißmann

Homburg, Germany

Location

Gemeinschaftspraxis Dr. Täschner / Dr. Bonigut

Leipzig, Germany

Location

Praxis Dr. Feige

Leipzig, Germany

Location

Gemeinschaftspraxis Schauermann

Meiningen, Germany

Location

Gemeinschaftspraxis Dres. med. Dittgen/Wilhelm/Rehlinger

Mettlach, Germany

Location

Hausarztpraxis Doreen Drews

Michendorf, Germany

Location

Hausarztpraxis Thorsten Drews

Michendorf, Germany

Location

Kardio Praxis Mülheim (Möllenberg)

Mülheim, Germany

Location

Dres. Bettenworth & Partner

Münster, Germany

Location

Gemeinschaftspraxis am Jahnufer (Schleß)

Neu-Ulm, Germany

Location

Kardiopraxis (Buchholz-Sanchez)

Neustadt, Germany

Location

Kardiologie am Weißen Turm (Stadelmann)

Nuremberg, Germany

Location

Praxis für Kardiologie (Laser)

Nuremberg, Germany

Location

Dres. Kornadt und Edel

Oberhausen, Germany

Location

Praxis Dr. Spengler

Panitzsch, Germany

Location

Kardiologische Praxis Papenburg Dr. Denchev

Papenburg, Germany

Location

Kardiologische Praxis Papenburg Dr. Malazhavy

Papenburg, Germany

Location

Kardiologische Praxis Papenburg Dr. Wilke

Papenburg, Germany

Location

MVZ ambulantes Kardiologisches Zentrum Peine gGmbH

Peine, Germany

Location

Kardiologe im MVZ Pfaffenhofen

Pfaffenhofen an der Ilm, Germany

Location

Hausärztlich-Kardiologisches MVZ am Felsenkeller

Pirna, Germany

Location

Kardiologische Gemeinschaftspraxis am Park Sanssouci (Janßen)

Potsdam, Germany

Location

Kardiologische Gemeinschaftspraxis am Park Sanssouci (Reibis)

Potsdam, Germany

Location

Nephrocare Püttlingen GmbH

Püttlingen, Germany

Location

Praxisklinik Salzatal

Salzatal, Germany

Location

Praxis Dr. Jax

Schwalmtal, Germany

Location

Parkkardiologie (Wolf)

Stahnsdorf, Germany

Location

Parkkardiologie (Wuttke)

Stahnsdorf, Germany

Location

Praxis Dr. Birkenhagen

Stollberg, Germany

Location

Kardiologische Gemeinschaftspraxis Dres. Klein & Neumann

Stuttgart, Germany

Location

Studienzentrum der Herzklinik Ulm GbR

Ulm, Germany

Location

Nephrologisches Zentrum Villingen Schwenningen (Hohenstein)

Villingen-Schwenningen, Germany

Location

Kardiologische Praxis (Elmas)

Waghäusel, Germany

Location

Praxis am Gutenbergplatz

Wiesbaden, Germany

Location

Praxis Gerschanik

Wuppertal, Germany

Location

Dres. Herrmann/Meyer/Teschner (Meyer)

Würzburg, Germany

Location

Praxis für Innere Medizin (Schwarz)

Zwenkau, Germany

Location

MeSH Terms

Conditions

Hypercholesterolemia

Interventions

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidEzetimibe

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

AzetidinesAzetinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 14, 2022

First Posted

September 19, 2022

Study Start

April 22, 2022

Primary Completion

November 17, 2022

Study Completion

November 17, 2022

Last Updated

December 1, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations